George Scangos compensation by year
Vir Biotechnology Summary Compensation Table · all 6 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|
| Salary | $512,019 | $514,583 | $544,583 | $575,000 | $638,333 | $325,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 | $7,479,180 | $2,489,730 | $0 |
| Option awards | $0 | $3,158,780 | $0 | $12,129,858 | $4,043,885 | $0 |
| Non-equity incentive | $260,000 | $260,044 | $438,900 | $487,000 | $295,750 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $11,000 | $11,200 | $11,400 | $11,600 | $12,200 | $13,200 |
| Total | $783,019 | $3,944,607 | $994,883 | $20,682,838 | $7,479,898 | $338,200 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vir Biotechnology, Inc. DEF 14A filed April 19, 2024, accession 0001140361-24-020684, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Vir Biotechnology, Inc. filed document, accession 0001140361-24-020684. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.
Equity holdings
unvested awards at FY2020 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 117,175 | — | $5.18 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Vir Biotechnology, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
2 Form 4 lines since the FY2023 proxy (filed April 19, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-02-24 | Sale | 10b5-1 | 10,056 | $9.45 | 698,239 |
| 2025-02-18 | Sale | 10b5-1 | 10,964 | $9.81 | 708,295 |
The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Vir Biotechnology’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Marianne De Backer | Chief Executive Officer and Director | $39,491,495 |
| Sung Lee | Former Executive Vice President and Chief Financial Officer | $4,848,374 |
| Jeffrey Calcagno | Executive Vice President and Chief Business Officer | $4,540,126 |
| Johanna Friedl-Naderer | Former Executive Vice President and Chief Operating Officer | $4,395,064 |
| Phillip Pang | Former Executive Vice President, Chief Medical Officer and Interim Head of Research | $3,952,190 |
| Steven Rice | Former Executive Vice President and Chief Administrative Officer | $3,260,800 |
| Ann Hanly | Executive Vice President and Chief Technology Officer | $3,113,931 |
| Howard Horn | Former Executive Vice President and Chief Financial Officer | $601,300 |
| George Scangos · this page | Former President and Chief Executive Officer | $338,200 |
Board service
Vir Biotechnology board · FY2023–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $39,557 | $0 | $0 | $0 | $39,557 |
| FY2024 | $61,250 | $83,120 | $124,963 | — | $269,333 |
| FY2023 | $25,000 | $0 | $0 | — | $25,000 |
Each year as the company reported it in Vir Biotechnology's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Vir Biotechnology pays directors a $50,000 cash retainer and $385,000 in Options and RSUs. As stated in Vir Biotechnology's FY2025 proxy.
Committees
Science and Technology
The full Vir Biotechnology compensation record
free company briefThis page is one person within Vir Biotechnology's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Vir Biotechnology proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vir Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.